Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Glaukos (GKOS) Short-Term Debt issuances (2015 - 2016)

Glaukos (GKOS) reported Short-Term Debt issuances of -$3.0 million for Q4 2016, down 40.48% year-over-year from -$5.1 million in Q1 2016, and down 35.35% on a QoQ basis from -$2.2 million in Q3 2016.

Glaukos (GKOS) has 2 years of Short-Term Debt issuances data on file, last reported at -$3.0 million in Q4 2016.

  • Quarterly Short-Term Debt issuances fell 40.48% year-over-year to -$3.0 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$9.7 million (down 24.24% YoY) and the FY2016 annual result came in at -$9.7 million, down 24.24% from the prior year.
  • Short-Term Debt issuances retreated to -$3.0 million in Q4 2016 per GKOS's latest filing, from -$2.2 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at -$1.4 million in Q2 2015 and bottomed at -$3.0 million in Q4 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt issuances (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn 31.00 Mn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -1.23 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -1.00 Mn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 37.80 Mn
10 Glaukos 6.00 Bn 5.90 Bn 117.23 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2016 -3.04 Mn
Dec 31, 2016 -3.04 Mn
Sep 30, 2016 -2.25 Mn
Sep 30, 2016 -2.25 Mn
Jun 30, 2016 -2.22 Mn
Jun 30, 2016 -2.22 Mn
Mar 31, 2016 -2.19 Mn
Mar 31, 2016 -2.19 Mn
Dec 31, 2015 -2.16 Mn
Dec 31, 2015 -2.16 Mn
Sep 30, 2015 -2.14 Mn
Sep 30, 2015 -2.14 Mn
Jun 30, 2015 -1.41 Mn
Jun 30, 2015 -1.41 Mn
Mar 31, 2015 -2.09 Mn
Mar 31, 2015 -2.09 Mn